id: calendar_year_to_moud_type_diversity
name: Calendar Year (2014-2021) â†’ MOUD Type Diversity
from_node:
  node_id: calendar_year
  node_name: Calendar Year (2014-2021)
to_node:
  node_id: moud_type_diversity
  node_name: MOUD Type Diversity
direction: positive
category: political
mechanism_pathway:
- 'Step 1: Policy changes and clinical guidelines evolved between 2014-2021 regarding
  MOUD use in pregnancy'
- 'Step 2: FDA guidance and prescribing regulations changed to allow broader use of
  buprenorphine-naloxone combinations and naltrexone'
- 'Step 3: Increased provider training and reduced stigma around non-methadone MOUD
  options'
- 'Step 4: Buprenorphine with naloxone and naltrexone became increasingly common in
  recent years of the study period'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Emmy L Tran et al. "Patterns of Medication for Opioid Use Disorder
    During Pregnancy, 7 Clinical Sites, MATernaL and Infant clinical NetworK (MAT-LINK),
    2014-2021.." *Journal of addiction medicine*. https://doi.org/10.1097/ADM.0000000000001426
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:05.666882'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: insurance_type
  direction: strengthens
  strength: moderate
  description: Private insurance may facilitate access to newer MOUD formulations
    more quickly than public insurance due to formulary differences
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/political/calendar_year_to_moud_type_diversity.yaml
_category: political
